• Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectively
  • Transformation supported by continuing existing cell therapy partnerships while exiting lasme-cel and eti-cel development
  • Realignment of the operating model targeting Cellectis cash runway extension into H2 2028